<DOC>
	<DOCNO>NCT01303926</DOCNO>
	<brief_summary>Cisplatin pemetrexed combination carboplatin , paclitaxel bevacizumab consider standard treatment non-squamous cell lung carcinoma ( NSCLC ) . Both main registrative trial consider positive reach objective , within , Quality Life ( QoL ) patient detail neither represent primary objective study . It consider , together enhancements added knowledge biology NSCLC , QoL may influence therapeutic choice one associations show well tolerate patient favour amelioration QoL .</brief_summary>
	<brief_title>Quality Life Comparison Advanced Non-squamous Non Small Cell Lung Cancer</brief_title>
	<detailed_description>The study aim primarily verify null hypothesis two scheme consideration minimal interesting difference ( MID ) ( i.e . difference clinical interest ) initial 3 month maintenance.EuroQ5D ( EQ5D ) questionnaire total score EQ5D visual analog scale ( VAS ) validate simple administered.The statistical hypothesis test describe perform t-test unpaired data ( equivalent non-parametric , pending verification normality distribution Shapiro-Wilk test ) , alpha error = 0.05 ( 2-sided ) . It assume : 1. 20 % randomized patient experienced progression disease time evaluation primary endpoint , 2. eventuality significantly different two treatment . The total sample enrol study increase 118 patient [ ( 49 +49 ) +20 % ) ]</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Written inform consent ( approved local Ethical Committee ) Histological type consist mainly nonsquamous histology define preferably stage IV metastatic disease stage IIIB presence supraclavicular lymph node accord parameter TNM 7th Ed , amenable curative therapy ECOG PS 01 Adequate bone marrow reserve Adequate hepatic , coagulative renal function Mixed NSCLC tumor mix adenosquamous carcinoma predominant squamous component histotype ( NSCLC SCLC ) adenosquamous form , predominant squamous component History gross hemoptysis &lt; 3 month prior enrollment history evidence inherit bleed diathesis coagulopathy risk bleeding . Tumors invade abut major blood vessel ( base radiologist assessment ) Evidence brain metastasis previously treat RT ( locoregional treatment ) Prior neoadjuvant adjuvant chemotherapy within six month prior study enrollment Previous radiotherapy last month study entry ( except radiotherapy symptomatic bone site risk cover premise measurable disease assessable ) A major surgery ( include open biopsy ) month precede study enrollment anticipation major surgery study Unable unwilling take folic acid vitamin B12 supplementation Unable unwilling take corticosteroid History gastrointestinal fistula , perforation , abscess , inflammatory bowel disease , diverticulitis Clinically significant thirdspace fluid collection , example , ascites pleural effusion control drainage procedure prior study entry Need take recently take ( within 10 day enrollment ) aspirin ( &gt; 325 mg/d ) , clopidogrel dos &gt; 75 mg/d , dipyramidole , ticlopidine , cilostazol . Patients also exclude hold nonsteroidal antiinflammatory agent , prophylactic therapy lowdose aspirin , 5day period cycle ( 8day period longacting agent , piroxicam ) Need take recently take ( within 10 day enrollment ) fulldose oral parenteral anticoagulant thrombolytic agent therapeutic purpose . Prophylactic use anticoagulant allow ; international normalize ratio ( INR ) &lt; 1.5 study enrollment History thrombotic disorder within last 6 month prior entry History hypertension , unless hypertension well control study entry ( ≤150/90 mm Hg ) patient stable regimen antihypertensive therapy . Patients prior history hypertensive crisis hypertensive encephalopathy Serious cardiac condition , myocardial infarction within 6 month , angina , heart disease , define New York Heart Association Class III IV Serious concomitant systemic disorder ( example , active infection include human immunodeficiency virus ) , opinion investigator , would compromise patient 's ability adhere protocol Receiving concurrent administration antitumor therapy Have second primary malignancy clinically detectable time consideration study enrollment Have prior malignancy NSCLC , carcinoma situ cervix , nonmelanoma skin cancer , unless prior malignancy diagnose definitively treat least 5 year previously subsequent evidence recurrence . Patients history low grade ( Gleason score ≤6 ) localize prostate cancer eligible even diagnose less 5 year previously Patients know hypersensitivity Chinese hamster ovary cell product recombinant human antibody</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>QoL</keyword>
	<keyword>EQ5D score</keyword>
	<keyword>cisplatin pemetrexed</keyword>
	<keyword>carboplatin paclitaxel bevacizumab</keyword>
	<keyword>maintenance</keyword>
</DOC>